(Q38042560)

27 August 2017

title

Teplizumab for treatment of type 1 diabetes mellitus (English)

1 reference

27 August 2017

0 references

Jessica W Skelley

1

1 reference

27 August 2017

Lindsey K Elmore

series ordinal

2

1 reference

27 August 2017

Jeffrey A Kyle

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

11 September 2012

1 reference

Annals of Pharmacotherapy

27 August 2017

published in

1 reference

27 August 2017

volume

46

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1405-1412

1 reference

Factors associated with early remission of type I diabetes in children treated with cyclosporine

27 August 2017

cites work

1 reference

Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group

21 January 2018

1 reference

Effects of Cyclosporine Immunosuppression in Insulin-Dependent Diabetes Mellitus of Recent Onset

21 January 2018

1 reference

Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice

21 January 2018

1 reference

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

21 January 2018

1 reference

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

21 January 2018

1 reference

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

21 January 2018

1 reference

TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes

21 January 2018

1 reference

CD3-specific antibody-induced active tolerance: from bench to bedside

21 January 2018

1 reference

Teplizumab therapy for type 1 diabetes

21 January 2018

1 reference

Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.

21 January 2018

1 reference

Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy

21 January 2018

1 reference

T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs

21 January 2018

1 reference

Central role for interleukin-2 in type 1 diabetes

21 January 2018

1 reference

Association between age, IL-10, IFNγ, stimulated C-peptide and disease progression in children with newly diagnosed Type 1 diabetes.

21 January 2018

1 reference

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years

21 January 2018

1 reference

Immunoprotection in spontaneous remission of type 1 diabetes: long-term follow-up results

21 January 2018

1 reference

Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1R065

1 reference

27 August 2017

1 reference